A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer

The treatment goals for metastatic breast cancer (MBC) are prolonging survival and improving the quality of life. Eribulin, a non-taxane tubulin inhibitor, demonstrated improved survival in previous studies and also showed mild toxicity when used in late-line therapy for MBC. We conducted a phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Takashima, Tsutomu, Tokunaga, Shinya, Tei, Seika, Nishimura, Shigehiko, Kawajiri, Hidemi, Kashiwagi, Shinichiro, Yamagata, Shigehito, Noda, Satoru, Nishimori, Takeo, Mizuyama, Yoko, Sunami, Takeshi, Tezuka, Kenji, Ikeda, Katsumi, Ogawa, Yoshinari, Onoda, Naoyoshi, Ishikawa, Tetsuro, Kudoh, Shinzoh, Takada, Minoru, Hirakawa, Kosei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766136/
https://www.ncbi.nlm.nih.gov/pubmed/27026861
http://dx.doi.org/10.1186/s40064-016-1833-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766136/
https://www.ncbi.nlm.nih.gov/pubmed/27026861
http://dx.doi.org/10.1186/s40064-016-1833-1

Ejemplares similares